ArticlePostepy dermatologii i alergologii2024
Is there still a place for neutrophil gelatinase-associated lipocalin to serve as a biomarker in psoriasis?
Article in Postepy dermatologii i alergologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) is believed to be involved in the pathogenesis of psoriasis, and its serum level was previously found to decline after administration of biologics, UV, and cyclosporine therapy. Aim: To investigate whether NGAL may serve as a biomarker of disease activity in psoriasis vulgaris. Material and methods: To measure the level of NGAL in serum, 36 patients with psoriasis vulgaris and 33 healthy controls were enrolled. Measurements were correlated to patients' and disease characteristics, including the Psoriasis Activity and Severity Index (PASI), Body Surface Area (BSA), itch and its intensity measured with the Peak Pruritus Numerical Rating Scale (PP-NRS), and involvement of special regions (scalp, genitals, hands, nails). Results: A significantly higher level of NGAL in serum was found in patients with psoriasis than in healthy controls. It showed a moderate correlation with PASI but none with BSA. The genital involvement was associated with significantly greater serum level of NGAL. Itch corresponded to higher concentration of NGAL, and PP-NRS corelated moderately with the level of circulating NGAL. Conclusions: An elevated level of circulating NGAL indicates its participation in the pathogenesis of psoriasis and the development of the itch. The serum level of NGAL does not allow for the evaluation of disease severity because it shows only moderate correlation with PASI. Determination of the circulating NGAL level may help to identify patients with greater risk for involvement of the genital region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.